tumor antigens

Two studies find that tumor-specific antigens are often peptides that result from a splicing event between exons and transposable elements.

This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.

Nanoparticle-coated bacteria can capture tumor antigens and deliver them to immune cells, triggering a response that improved survival rates in mice.

Nanoparticle-coated bacteria carry cancer-derived proteins to dendritic cells, enabling the immune system to launch a response in a mouse model.

Because most people are vaccinated against tetanus as children, delivering benign bacteria carrying a tetanus antigen into pancreatic tumors makes them visible to memory cells in the immune system, researchers report.

By screening for novel tumor targets, researchers build better CAR-T cell therapies.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.

Injecting immunostimulants directly into the tumor is not a new strategy to stimulate the immune system, but the approach has seen a surge of interest in recent years.

Analyzing single cell sequences to decipher the evolution of a tumor